These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36520261)

  • 1. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects.
    Khadela A; Soni S; Megha K; Shah AC; Pandya AJ; Kothari N; Shah I; Avinash CB
    Med Oncol; 2022 Dec; 40(1):48. PubMed ID: 36520261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research progress on immunotherapy in triple‑negative breast cancer (Review).
    Zhang X; Ge X; Jiang T; Yang R; Li S
    Int J Oncol; 2022 Aug; 61(2):. PubMed ID: 35762339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.
    Das K; Paul S; Ghosh A; Gupta S; Mukherjee T; Shankar P; Sharma A; Keshava S; Chauhan SC; Kashyap VK; Parashar D
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of triple-negative breast cancer.
    Kumar P; Aggarwal R
    Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
    Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
    Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
    Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
    Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
    Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
    Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
    BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in targeted strategies for triple-negative breast cancer.
    Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple negative breast cancer: special histological types and emerging therapeutic methods.
    Cao L; Niu Y
    Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress and challenges of immunotherapy in triple-negative breast cancer.
    Zhu Y; Zhu X; Tang C; Guan X; Zhang W
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.